Q2 STOCKS TO BUY

ORPH Falls From Speculative Surge After FDA Rejection

Orphazyme was briefly a victim of the meme stock frenzy

Digital Content Manager
Jun 18, 2021 at 9:53 AM
facebook X logo linkedin


The shares of Orphazyme A S ADR (NASDAQ:ORPH) are dramatically lower this morning, slammed by news that the Food and Drug Administration (FDA) rejected the firm's experimental genetic disorder drug candidate, arimoclomol. The Danish biotech has recently been dubbed a meme stock, surging to an unprecedented high of $77.77 earlier in the month. One analyst from Nordnet now calls the situation "hopeless," as the FDA's decision has left ORPH with no money or documentable projects, adding that its "game over for 'meme speculation'."

The security was last seen down 38.9%  at $8.40, putting it even closer to its lows near the $5 level. ORPH just breached its 70-day moving average, too, which looked for a second like it could support the stock's pullback from its early June surge. Orphazyme stock is still up 57.5% in the last month, however. 

This drop could lead to price-target cuts. The 12-month consensus price target of $10.50 is a whopping 45.8% to last night's close. Meanwhile, of the three analysts in coverage, there is only one "buy" rating  on the books. 

While short interest has waned from its March highs, it shot up in the last reporting period to 35,295 shares sold short. There's a good possibility more short sellers will pile on, should this negative price action continue, as these shares only make up 0.1% of the stock's available float. It should be noted, however, ORPH has landed on the short-sell restricted (SSR) list today. 

 

 
 

“Buy This Stock Now!” - Expert Who Called 11x On TSLA

He called a rare 11x on Tesla…

But now, thanks to Elon & Trump’s new alliance…

He says there’s a new opportunity that could be 1,000x BIGGER than Tesla – and it could completely revolutionize a $23 Trillion market.

It’s trading for less than $5 per share right now…

But it won’t be under the radar for long.

Discover The 1,000x Bigger Elon Opportunity Here

GRAND SLAM COUNTDOWN

 
 

Featured Articles from Trusted Partners:

👀Learn How Dividends Create Passive Income for Life
Receive $200 Off Motley Fool Epic. The Motley Fool Epic $299 discounted offer is based on $499/year list price. Introductory promotion for new members only. Take control of your money and your portfolio with Motley Fool Epic.

💵New Income System Could Pay You $4,243 Monthly
You could collect an average of $4,243 per month starting as early as next week with a new payout system for income investors. New registrations are being accepted for investors who want to be in a position to start with their first payout next week.

🚀Easy 92% Crypto Dividends (No Coins Required)
COIN stock doesn't pay a dividend... But there's actually a new way to collect a massive dividend that's indirectly based on the stock and offers a terrific monthly income (currently yielding nearly 92% on a forward basis).

🤝Free Advisor Match with Wiseradvisor.com
Don't leave your retirement to chance! Get matched with a trusted financial expert for FREE and make the most of your tax refund. Get started now.

⚠️Dennis Quaid's #1 Warning for Americans
Here's the thing: life doesn't come with guarantees. The economy shifts, markets stumble, and years of hard work could slip through your fingers like sand. But it doesn't have to be that way for you. So request a free copy of this Gold & Silver Guide that will arrive right to your doorstep when you act now.

 

 
 

Follow us on X, Follow us on Twitter